639 related articles for article (PubMed ID: 15650854)
1. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.
Coassin M; Lambiase A; Costa N; De Gregorio A; Sgrulletta R; Sacchetti M; Aloe L; Bonini S
Graefes Arch Clin Exp Ophthalmol; 2005 Feb; 243(2):151-5. PubMed ID: 15650854
[TBL] [Abstract][Full Text] [Related]
2. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Clinical, Diagnostic, and Advanced Imaging Characterization of the Ocular Surface in Spontaneous Aqueous Deficient Dry Eye Disease in Dogs.
Leonard BC; Stewart KA; Shaw GC; Hoehn AL; Stanley AA; Murphy CJ; Thomasy SM
Cornea; 2019 Dec; 38(12):1568-1575. PubMed ID: 31369464
[TBL] [Abstract][Full Text] [Related]
4. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
Moore CP; McHugh JB; Thorne JG; Phillips TE
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
[TBL] [Abstract][Full Text] [Related]
5. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
6. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye.
Jain P; Li R; Lama T; Saragovi HU; Cumberlidge G; Meerovitch K
Exp Eye Res; 2011 Oct; 93(4):503-12. PubMed ID: 21726552
[TBL] [Abstract][Full Text] [Related]
7. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome.
Žiniauskaite A; Ragauskas S; Hakkarainen JJ; Rich CC; Baumgartner R; Kalesnykas G; Albers DS; Kaja S
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3088-3093. PubMed ID: 30025146
[TBL] [Abstract][Full Text] [Related]
9. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca.
Berdoulay A; English RV; Nadelstein B
Vet Ophthalmol; 2005; 8(4):225-32. PubMed ID: 16008701
[TBL] [Abstract][Full Text] [Related]
10. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
11. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
12. The effects of topical aqueous sirolimus on tear production in normal dogs and dogs with refractory dry eye.
Spatola R; Nadelstein B; Berdoulay A; English RV
Vet Ophthalmol; 2018 May; 21(3):255-263. PubMed ID: 28972684
[TBL] [Abstract][Full Text] [Related]
13. Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial.
Chen T; Powell CC
Vet Ophthalmol; 2015 Nov; 18(6):497-501. PubMed ID: 25675975
[TBL] [Abstract][Full Text] [Related]
14. A new nonhuman primate model of severe dry eye.
Qin Y; Tan X; Zhang Y; Jie Y; Labbe A; Pan Z
Cornea; 2014 May; 33(5):510-7. PubMed ID: 24576920
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.
Morgan RV; Abrams KL
J Am Vet Med Assoc; 1991 Oct; 199(8):1043-6. PubMed ID: 1748607
[TBL] [Abstract][Full Text] [Related]
16. Effects of DA-6034 on aqueous tear fluid secretion and conjunctival goblet cell proliferation.
Choi SM; Lee YG; Seo MJ; Kang KK; Ahn BO; Yoo M
J Ocul Pharmacol Ther; 2009 Jun; 25(3):209-14. PubMed ID: 19456255
[TBL] [Abstract][Full Text] [Related]
17. Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca.
Radziejewski K; Balicki I; Szadkowski M
Acta Vet Hung; 2018 Jun; 66(2):189-203. PubMed ID: 29958527
[TBL] [Abstract][Full Text] [Related]
18. Tear protein profiles vs. clinical characteristics of untreated and cyclosporine-treated canine KCS.
Fullard RJ; Kaswan RM; Bounous DI; Hirsh SG
J Am Optom Assoc; 1995 Jul; 66(7):397-404. PubMed ID: 7560726
[TBL] [Abstract][Full Text] [Related]
19. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
20. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy.
Gao J; Schwalb TA; Addeo JV; Ghosn CR; Stern ME
Cornea; 1998 Nov; 17(6):654-63. PubMed ID: 9820947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
